Latest 5 stories · newest Nov 2, 2026
CorMedix announced $355 million in cash and reaffirmed 2026 revenue guidance of $325M-$345M, anticipating a DefenCath reimbursement increase for Q1 2027. Management indicated that Add-on projected rates in 2027 will exceed current levels.
The FDA accepted the supplemental NDA with a target action date of Q1 2027, supported by the ReSPECT Phase III trial. This milestone marks a significant regulatory step toward addressing the high mortality rates associated with invasive fungal diseases.
Actinium Pharmaceuticals announced the appointment of Matt David, M.D., as Chief Financial Officer to lead finance and capital markets functions. This strategic leadership addition may enhance investor relations as the company advances its targeted radiotherapy pipeline.
CorMedix agreed to settle pending derivative lawsuits with a hearing set for September 23, 2026.
CorMedix's subsidiary Melinta won a patent litigation case where the Federal Circuit upheld findings that Nexus Pharmaceuticals infringed MINOCIN patents and affirmed a permanent injunction blocking generic competition. The decision protects CorMedix's market exclusivity for its intravenous minocycl…
The same CRMD feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/CRMD/newsSTART FREE